enVVeno Medical Corporation
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NVNO | VPT.V | ENOV | AORT | EW | INFU | |
|---|---|---|---|---|---|---|
| Market cap | 4.86M | 13.50M | 1.41B | 1.29B | 57.28B | 261.91M |
| P/E (TTM) | — | — | — | — | 59.1 | 32.9 |
| Forward P/E | -1.1 | — | 6.9 | 35.3 | 29.4 | 25.3 |
| Price/book | 0.3 | -3.5 | 1.0 | 2.9 | 5.6 | 4.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −69.51% | −30.00% | −14.07% | −44.32% | +20.54% | +28.00% |
| Today | −2.43% | −6.67% | +16.90% | +11.56% | +4.39% | +2.73% |
The closest companies by business and industry (Medical Devices). Prices may be delayed up to 15 min.
Latest news
All NVNO news ›enVVeno Medical to Showcase the enVVe System at 38th Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium
Featured as an emerging technology and innovation in endovascular medicine, the presentation will highlight the potential of enVVe to address the significant unmet need in deep venous disease IRVINE, CA / ACCESS Newswire / November 2, 2026…
enVVeno Medical (NASDAQ:NVNO) Stock Rating Lowered by Wall Street Zen
Posted by Tristan Rich on Nov 3rd, 2026 enVVeno Medical (NASDAQ:NVNO – Get Free Report) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Sunday, Wall Street Zen reports.…
enVVeno Medical Reports Third Quarter 2026 Financial Results and Prepares to Treat First Patients in FDA-Approved TAVVE Pivotal Study
Initial 10-patient stage of U.S. pivotal study of the first-in-class enVVe non-surgical replacement venous valve on track to begin before year end Cash and investments of $18.5 million expected to fund operations into Q4 2027, including…
enVVeno Medical GAAP EPS of -$6.29 misses by $3.94
enVVeno Medical press release (NVNO): Q3 GAAP EPS of -$6.29 misses by $3.94. As of September 30, 2026, enVVeno had cash and investments of approximately $18.5 m - enVVeno Medical press release (NVNO): Q3 GAAP EPS of -$6.29 misses by $3.94.…
enVVeno Medical Releases New Episode of "WTF" Video Series Featuring CEO Rob Berman
FinancialContent IRVINE, CA / ACCESS Newswire / October 21, 2026 / enVVeno Medical Corporation (NASDAQ: NVNO) ("enVVeno Medical" or the "Company"), today announced the release of the third episode of its video series
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- seekingalpha.com2
- guardonline.com1
- markets.financialcontent.com1
- rutlandherald.com1
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.